The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database
- 1 July 2014
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (10) , 1847-1853
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialAnnals of Oncology, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Recommendations for the assessment of progression in randomised cancer treatment trialsEuropean Journal of Cancer, 2009
- Individual patient data analysis to assess modifications to the RECIST criteriaEuropean Journal of Cancer, 2009
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Survival Model Predictive Accuracy and ROC CurvesBiometrics, 2005
- Facts and Controversies in Systemic Treatment of Metastatic Breast CancerThe Oncologist, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000